FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051992029> ?p ?o ?g. }

• W2051992029 endingPage "70" @default.
• W2051992029 startingPage "565" @default.
• W2051992029 abstract "Our objectives were to assess the efficacy and toxicity of gemcitabine plus cisplatin as first-line therapy in metastatic breast cancer (MBC). Patients with stage IV MBC and no prior chemotherapy for metastatic disease were treated with gemcitabine 1200 mg/m on days 1 and 8, and cisplatin 75 mg/m on day 1 every 21 days. Up to 6 cycles were given. A total of 46 patients with a median age of 49 years (range 24-77) and Karnofsky performance status of 80 or above were enrolled. In total, 238 cycles were administered. Of the 42 patients evaluable for response, seven (17%) achieved a complete response and 27 (64%) a partial response, for an overall response rate of 81% [95% confidence interval (CI) 69-93%]. Median time to progression was 14.9 months (95% CI 0-30.2 months). Median duration of response was 24.2 months (95% CI 11.2-37.3 months). The median survival was 27.9 months (95% CI 23.1-32.7 months), and the 1- and 2-year survival probabilities were 71.4 and 61.4%, respectively. All patients were evaluable for toxicity, and grade 3/4 WHO toxicities included neutropenia (41.3%), anemia (8.7%), thrombocytopenia (8.7%), alopecia (26.1%) and nausea/vomiting (32.6%). We conclude that gemcitabine plus cisplatin is a highly effective and safe first-line treatment for patients with MBC. The time to progression of 14.9 months compares favorably with other standard treatments (anthracyclines, taxanes). A randomized study is required to further investigate the role of this combination as first-line treatment for MBC." @default.
• W2051992029 created "2016-06-24" @default.
• W2051992029 creator A5003297835 @default.
• W2051992029 creator A5009526240 @default.
• W2051992029 creator A5017094048 @default.
• W2051992029 creator A5023679870 @default.
• W2051992029 creator A5031568903 @default.
• W2051992029 creator A5036984707 @default.
• W2051992029 creator A5037283675 @default.
• W2051992029 creator A5045400076 @default.
• W2051992029 creator A5052371243 @default.
• W2051992029 creator A5068612383 @default.
• W2051992029 date "2006-06-01" @default.
• W2051992029 modified "2023-09-27" @default.
• W2051992029 title "Phase II study of gemcitabine plus cisplatin in metastatic breast cancer." @default.
• W2051992029 cites W1812067939 @default.
• W2051992029 cites W1871271676 @default.
• W2051992029 cites W1971473564 @default.
• W2051992029 cites W1972888300 @default.
• W2051992029 cites W1997838307 @default.
• W2051992029 cites W2001996041 @default.
• W2051992029 cites W2003476023 @default.
• W2051992029 cites W2013246214 @default.
• W2051992029 cites W2019010537 @default.
• W2051992029 cites W2028375263 @default.
• W2051992029 cites W2045316633 @default.
• W2051992029 cites W2052771009 @default.
• W2051992029 cites W2068532424 @default.
• W2051992029 cites W2069991705 @default.
• W2051992029 cites W2071205059 @default.
• W2051992029 cites W2083470546 @default.
• W2051992029 cites W2084562398 @default.
• W2051992029 cites W2090906593 @default.
• W2051992029 cites W2216172761 @default.
• W2051992029 cites W4255483444 @default.
• W2051992029 doi "https://doi.org/10.1097/00001813-200606000-00011" @default.
• W2051992029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16702814" @default.
• W2051992029 hasPublicationYear "2006" @default.
• W2051992029 type Work @default.
• W2051992029 sameAs 2051992029 @default.
• W2051992029 citedByCount "16" @default.
• W2051992029 countsByYear W20519920292016 @default.
• W2051992029 crossrefType "journal-article" @default.
• W2051992029 hasAuthorship W2051992029A5003297835 @default.
• W2051992029 hasAuthorship W2051992029A5009526240 @default.
• W2051992029 hasAuthorship W2051992029A5017094048 @default.
• W2051992029 hasAuthorship W2051992029A5023679870 @default.
• W2051992029 hasAuthorship W2051992029A5031568903 @default.
• W2051992029 hasAuthorship W2051992029A5036984707 @default.
• W2051992029 hasAuthorship W2051992029A5037283675 @default.
• W2051992029 hasAuthorship W2051992029A5045400076 @default.
• W2051992029 hasAuthorship W2051992029A5052371243 @default.
• W2051992029 hasAuthorship W2051992029A5068612383 @default.
• W2051992029 hasConcept C121608353 @default.
• W2051992029 hasConcept C126322002 @default.
• W2051992029 hasConcept C141071460 @default.
• W2051992029 hasConcept C143998085 @default.
• W2051992029 hasConcept C2775930923 @default.
• W2051992029 hasConcept C2776694085 @default.
• W2051992029 hasConcept C2777063308 @default.
• W2051992029 hasConcept C2778239845 @default.
• W2051992029 hasConcept C2778248108 @default.
• W2051992029 hasConcept C2780258809 @default.
• W2051992029 hasConcept C2780580376 @default.
• W2051992029 hasConcept C29730261 @default.
• W2051992029 hasConcept C31760486 @default.
• W2051992029 hasConcept C530470458 @default.
• W2051992029 hasConcept C71924100 @default.
• W2051992029 hasConcept C90924648 @default.
• W2051992029 hasConceptScore W2051992029C121608353 @default.
• W2051992029 hasConceptScore W2051992029C126322002 @default.
• W2051992029 hasConceptScore W2051992029C141071460 @default.
• W2051992029 hasConceptScore W2051992029C143998085 @default.
• W2051992029 hasConceptScore W2051992029C2775930923 @default.
• W2051992029 hasConceptScore W2051992029C2776694085 @default.
• W2051992029 hasConceptScore W2051992029C2777063308 @default.
• W2051992029 hasConceptScore W2051992029C2778239845 @default.
• W2051992029 hasConceptScore W2051992029C2778248108 @default.
• W2051992029 hasConceptScore W2051992029C2780258809 @default.
• W2051992029 hasConceptScore W2051992029C2780580376 @default.
• W2051992029 hasConceptScore W2051992029C29730261 @default.
• W2051992029 hasConceptScore W2051992029C31760486 @default.
• W2051992029 hasConceptScore W2051992029C530470458 @default.
• W2051992029 hasConceptScore W2051992029C71924100 @default.
• W2051992029 hasConceptScore W2051992029C90924648 @default.
• W2051992029 hasIssue "5" @default.
• W2051992029 hasLocation W20519920291 @default.
• W2051992029 hasLocation W20519920292 @default.
• W2051992029 hasOpenAccess W2051992029 @default.
• W2051992029 hasPrimaryLocation W20519920291 @default.
• W2051992029 hasRelatedWork W1967786039 @default.
• W2051992029 hasRelatedWork W1972888300 @default.
• W2051992029 hasRelatedWork W2026791198 @default.
• W2051992029 hasRelatedWork W2085978374 @default.
• W2051992029 hasRelatedWork W2100029565 @default.
• W2051992029 hasRelatedWork W2379223378 @default.
• W2051992029 hasRelatedWork W2381460883 @default.
• W2051992029 hasRelatedWork W2383640614 @default.

• next